Evidence map›Paper›PMID 36679979›Full record

ArticleVaccines2023

Assessment of Antibody-Titer Changes after Second and Third Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination in Japanese Post-Kidney-Transplant Patients.

Kumiko Fujieda, Akihito Tanaka, Ryosuke Kikuchi, Nami Takai, Shoji Saito, Yoshinari Yasuda, Takashi Fujita, Masashi Kato, Kazuhiro Furuhashi, Shoichi Maruyama

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kumiko FujiedaDepartment of Nephrology, Nagoya University Hospital, Nagoya 466-8560, Aichi, Japan.ORCID 0000-0003-2086-9507
Akihito TanakaDepartment of Nephrology, Nagoya University Hospital, Nagoya 466-8560, Aichi, Japan.ORCID 0000-0001-8866-5901
Ryosuke KikuchiDepartment of Medical Technique, Nagoya University Hospital, Nagoya 466-8560, Aichi, Japan.
Nami TakaiDepartment of Nursing, Nagoya University Hospital, Nagoya 466-8560, Aichi, Japan.
Shoji SaitoDepartment of Nephrology, Nagoya University Hospital, Nagoya 466-8560, Aichi, Japan.ORCID 0000-0002-8235-8086
Yoshinari YasudaDepartment of Nephrology, Nagoya University Hospital, Nagoya 466-8560, Aichi, Japan.
Takashi FujitaDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Aichi, Japan.
Masashi KatoDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Aichi, Japan.
Kazuhiro FuruhashiDepartment of Nephrology, Nagoya University Hospital, Nagoya 466-8560, Aichi, Japan.ORCID 0000-0003-2476-688X
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Aichi, Japan.
Nagoya University Hospital · JPNagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-renal-transplant patients have a relatively low antibody-acquisition rate following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination. In this study, antibody titers were measured 5−6 months and 3 weeks to 3 months after the second and third SARS-CoV-2 mRNA vaccinations, respectively. Post-renal-transplant patients visiting our hospital who had received three SARS-CoV-2 mRNA vaccine doses were included in the study. SARS-CoV-2 immunoglobulin G antibody titers were measured three times: between 3 weeks and 3 months after the second vaccination, 5−6 months after the second vaccination, and between 3 weeks and 3 months after the third vaccination. A total of 62 (40 men and 22 women) were included, 44 of whom (71.0%) were antibody positive after their third vaccination. On comparing the antibody-acquired and antibody-non-acquired groups, body mass index (BMI, odds ratio [OR]: 1.44, 95% confidence interval [CI]: 1.07−1.93, p < 0.05) and the estimated glomerular filtration rate (eGFR, OR: 1.14, 95% CI: 1.06−1.24, p < 0.01) were associated with antibody acquisition. Therefore, in Japanese post-kidney-transplant patients, increases in the antibody-acquisition rate and absolute antibody titer after the third vaccination were observed, with BMI and eGFR associated with the antibody-acquisition rate.

Indexed as

immunocompromised hostkidney transplantationSARS-CoV-2vaccination

Identifiers

PMID36679979
PMCPMC9866315
OpenAlexW4313646761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.